Characterization of tumor-associated B-cell subsets in patients with colorectal cancer

Oncotarget

Volumn 5, Issue 13, 2014, Pages 4651-4664

  Shimabukuro Vornhagen, Alexander ^a   Schlößer, Hans A ^a   Gryschok, Luise ^a   Malcher, Joke ^a   Wennhold, Kerstin ^a   Garcia Marquez, Maria ^a   Herbold, Till ^a   Neuhaus, Laura S ^a   Becker, Hans J ^a   Fiedler, Anne ^a   Scherwitz, Pascal ^b   Koslowsky, Thomas ^c   Hake, Roland ^c   Stippel, Dirk L ^a   Hölscher, Arnulf H ^a   Eidt, Sebastian ^c   Hallek, Michael ^a   Theurich, Sebastian ^a   von Bergwelt Baildon, Michael S ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Marien Hospital   (Germany)

^c St Elisabeth Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR7; IMMUNOGLOBULIN D; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; KI 67 ANTIGEN; LEUKOCYTE ANTIGEN;

ADVANCED CANCER; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; COLORECTAL CANCER; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MEMORY T LYMPHOCYTE; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CELL; REGULATORY B CELL; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INFILTRATING B CELL; BLOOD; COLORECTAL TUMOR; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; KI-67 ANTIGEN; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLASMA CELLS;

EID: 84905018222     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1701     Document Type: Article

References (54)

1. Schreiber RD, Old LJ and Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; Mar 25;331(6024):1565-70.
2. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010; Nov 1;185(9):4977-82.
3. DiLillo DJ, Yanaba K and Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol. 2010; Apr 1;184(7):4006-16.
4. Ammirante M, Luo J-L, Grivennikov S, Nedospasov S and Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010; Mar 11;464(7286):302-5.
5. Jahrsdörfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS, Taylor CM and Weiner GJ. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood. 2006; Oct 15;108(8):2712-9.
6. Zhang Y, Eliav Y, Shin S-U, Schreiber TH, Podack ER, Tadmor T and Rosenblatt JD. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer immunology, immunotherapy: CII. 2012; Jul 8;
7. Menegaz RA, Michelin MA, Etchebehere RM, Fernandes PCJ and Murta EFC. Peri-and intratumoral T and B lymphocytic infiltration in breast cancer. European Journal of Gynaecological Oncology. 2008; 29;(4):321-6.
8. Yasuda M, Takenoyama M, Obata Y, Sugaya M, So T, Hanagiri T, Sugio K and Yasumoto K. Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer. Cancer research. 2002; 62;(6):1751-6.
9. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH and Nelson BH. CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012; Jun 15;18(12):3281-92.
10. Maletzki C, Jahnke A, Ostwald C, Klar E, Prall F and Linnebacher M. Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG. PLoS ONE. 2012; 7(2):e32639.
11. Willis SN, Mallozzi SS, Rodig SJ, Cronk KM, McArdel SL, Caron T, Pinkus GS, Lovato L, Shampain KL, Anderson DE, Anderson RCE, Bruce JN and O'Connor KC. The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response. Journal of Immunology (Baltimore, Md: 1950). 2009; 182(5):3310-7.
12. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW and Tedder TF. Characterization of a rare IL-10-competent B-cell subset in man that parallels mouse regulatory B10 cells. Blood [Internet]. 2010; Oct 20 [cited 2010 Nov 4]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/20962324.
13. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP and Biragyn A. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res. 2011; May 15;71 (10):3505-15.
14. Ray A, Basu S, Williams CB, Salzman NH and Dittel BN. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol. 2012; Apr 1;188(7):3188-98.
15. Gooden MJM, de Bock GH, Leffers N, Daemen T and Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011; Jun 28;105(1):93-103.
16. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, DranoffG, Giovannucci EL and Fuchs CS. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009; Oct 15;15(20):6412-20.
17. De Miranda NFCC, Goudkade D, Jordanova ES, Tops CMJ, Hes FJ, Vasen HFA, van Wezel T and Morreau H. Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases. Clin Cancer Res. 2012; Mar1;18(5):1237-45.
18. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, NY. 2006; 313(5795):1960-4.
19. Fremd C, Schuetz F, Sohn C, Beckhove P and Domschke C. B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology. 2013; Jul 1;2(7):e25443.
20. De Visser KE, Korets LV and Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005; May; 7(5):411-23.
21. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH and Rosenblatt JD. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. International journal of cancer. 2005; 117(4):574-86.
22. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM and Balkwill FR. B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci USA. 2011; Jun 28;108(26):10662-7.
23. Balkwill F, Montfort A and Capasso M. B regulatory cells in cancer. Trends Immunol. 2013; Apr;34(4):169-73.
24. Qin Z, Richter G, Schuler T, Ibe S, Cao X and Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nature medicine. 1998;4(5):627-30.
25. Inoue S, Leitner WW, Golding B and Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer research. 2006;66(15):7741-7.
26. Staquicini FI, Tandle A, Libutti SK, Sun J, Zigler M, Bar-Eli M, Aliperti F, Pérez EC, Gershenwald JE, Mariano M, Pasqualini R, Arap W and Lopes JD. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 2008; Oct 15;68(20):8419-28.
27. Ruddell A, Harrell MI, Furuya M, Kirschbaum SB and Iritani BM. B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma. Neoplasia. 2011; Aug;13(8):748-57.
28. Quan N, Zhang Z, Demetrikopoulos MK, Kitson RP, Chambers WH, Goldfarb RH and Weiss JM. Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat. Cancer Res. 1999; Mar 1; 59(5):1080-9.
29. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie J-J, Rochaix P and Girard J-P. Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011; Sep 1;71(17):5678-87.
30. Eiró N, Pidal I, Fernandez-Garcia B, Junquera S, Lamelas ML, Del Casar JM, González LO, López-Muñiz A and Vizoso FJ. Impact of CD68/(CD3+CD20) Ratio at the Invasive Front of Primary Tumors on Distant Metastasis Development in Breast Cancer. PLoS ONE. 2012;7(12):e52796.
31. Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, Li S and Chang AE. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res. 2011; Aug 1;17(15):4987-95.
32. Jackaman C, Cornwall S, Graham PT and Nelson DJ. CD40-activated B cells contribute to mesothelioma tumor regression. Immunol Cell Biol. 2011; Feb 89;(2):255-67.
33. Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH and Mason NJ. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS ONE. 2011;6(8):e24167.
34. Ding C, Wang L, Marroquin J and Yan J. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood. 2008; Oct 1;112(7):2817-25.
35. Julien S, Picco G, Sewell R, Vercoutter-Edouart A-S, Tarp M, Miles D, Clausen H, Taylor-Papadimitriou J, Burchell JM. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer. 2009; Jun 2;100(11):1746-54.
36. CandolfiM, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, Foulad D, Muhammad AKMG, Salehi S, Keech N, Puntel M, Liu C, Sanderson NR, Kroeger KM, Dunn R, Martins G and et al. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia. 2011; Oct; 13(10):947-60.
37. Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A and Bosa M. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011; Mar 1;29(7):814-24.
38. Barbera-Guillem E, Nelson MB, Barr B, Nyhus JK, May KF, Feng L and Sampsel JW. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother. 2000; 48;(10):541-9.
39. Wejksza K, Lee-Chang C, Bodogai M, Bonzo J, Gonzalez FJ, Lehrmann E, Becker K and Biragyn A. Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α. J Immunol. 2013; Mar 15;190(6):2575-84.
40. Zirakzadeh AA, Marits P, Sherif A and Winqvist O. Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies. J Immunol. 2013; Jun 1;190(11):5847-55.
41. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR and Trajanoski Z. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; Oct 17;39(4):782-95.
42. Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang K-M, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM and Vonderheide RH. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res. 2009; Jul 1;15(13):4277-87.
43. Richards CH, Flegg KM, Roxburgh CSD, Going JJ, Mohammed Z, Horgan PG and McMillan DC. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer. 2012; Jun 5;106(12):2010-5.
44. Mohammed ZMA, Going JJ, Edwards J, Elsberger B, Doughty JC and McMillan DC. The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2012; Aug 21;107(5):864-73.
45. Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, Berglund A, Lambe M, Holmberg L, Ekman S, Bergqvist M, Pontén F, Cadenas C, Marchan R, Hengstler JG and Rahnenführer J. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013; Jan 28.
46. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K and et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin k C as a compatible prognostic marker in human solid tumors. Clin Cancer Res. 2012; May 1;18(9):2695-703.
47. Pavoni E, Monteriu G, Santapaola D, Petronzelli F, Anastasi AM, Pelliccia A, D'Alessio V, De Santis R and Minenkova O. Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. BMC Biotechnology. 2007;7:70.
48. Nzula S, Going JJ and Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res. 2003; Jun 15;63(12):3275-80.
49. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman W-H, Pagès F and Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011; Feb 15;71(4): 1263-71.
50. Bodogai M, Lee-Chang C, Wejksza K, Lai J-P, Merino M, Wersto RP, Gress RE, Chan AC, Hesdorffer C and Biragyn A. Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res. 2013; Jan 30.
51. Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA and Miller LD. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol. 2013; Apr 24;14(4):R34.
52. Camus M, Tosolini M, Mlecnik B, Pagès F, Kirilovsky A, Berger A, Costes A, Bindea G, Charoentong P, Bruneval P, Trajanoski Z, Fridman W-H and Galon J. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009; Mar 15;69(6):2685-93.
53. Hernberg M, Turunen JP, Muhonen T and Pyrhönen S. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother. 1997; Nov 20;(6):488-95.
54. Gu-Trantien C and Willard-Gallo K. Tumor-infiltrating follicular helper T cells: The new kids on the block. Oncoimmunology. 2013; Oct 1;2(10):e26066.